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Becaplermin gel in the treatment of pressure ulcers: a phase 
II randomized, double-blind, placebo-controlled study
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Pressure ulcers are associated with significant rates of morbidity and mortality, particularly in the geriatric and spinal
cord–injured populations. Newer pharmacologically active therapies include the use of topically applied recombinant
human platelet-derived growth factor-BB (becaplermin), the active ingredient in REGRANEX® (becaplermin) Gel 0.01%,
which has been approved in the United States for treatment of lower extremity diabetic neuropathic ulcers that extend
into the subcutaneous tissue or beyond and have an adequate blood supply. In this study, the efficacy of becaplermin
gel in the treatment of chronic full thickness pressure ulcers was compared with that of placebo gel. A total of 124
adults (≥ 18 years of age) with pressure ulcers were assigned randomly to receive topical treatment with becaplermin
gel 100 µg/g (n = 31) or 300 µg/g (n = 32) once daily alternated with placebo gel every 12 hours, becaplermin gel 100
µg/g twice daily (n = 30), or placebo (sodium carboxymethylcellulose) gel (n = 31) twice daily until complete healing
was achieved or for 16 weeks. All treatment groups received a standardized regimen of good wound care throughout
the study period. Study endpoints were the incidence of complete healing, the incidence of ≥ 90% healing, and the
relative ulcer volume at endpoint (endpoint/baseline). Once-daily treatment of chronic pressure ulcers with becapler-
min gel 100 µg/g or 300 µg/g significantly increased the incidences of complete and ≥ 90% healing and significantly
reduced the median relative ulcer volume at endpoint compared with that of placebo gel (p < 0.025 for all compari-
sons). Becaplermin gel 300 µg/g did not result in a significantly greater incidence of healing than that observed with
100 µg/g. Treatment with becaplermin gel was generally well tolerated and the incidence of adverse events was similar
among treatment groups. In conclusion, once-daily application of becaplermin gel is efficacious in the treatment of
chronic full thickness pressure ulcers. (WOUND REP REG 1999;7:141–147)
Pressure ulcers are a prevalent clinical problem. Con-
servative estimates indicate that in the United States
alone, over 2 million people in hospitals and nursing
homes are afflicted with these wounds annually.1
Pressure ulcers are associated with significant rates
of morbidity and mortality, particularly in the geriat-
ric and spinal cord–injured populations.2,3 Patients
who develop pressure ulcers suffer pain and discom-
fort, often have an increased length of stay in hospitals
and longer rehabilitation time, and use considerably
more resources than patients who do not develop pres-
sure ulcers.4,5
Pressure ulcers have a great impact on morbidity
and mortality. As a result, patients with pressure
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ulcers often have prolonged and expensive hospital-
izations. The mean length of stay for a patient with
a primary diagnosis of pressure ulcer was nearly 5
times greater than that of patients without pressure
ulcers in one cross sectional study.4,6 The increased
length of stay and higher resource utilization in
patients with pressure ulcers translates into signif-
icant costs: the mean hospital charge for patients
with a primary diagnosis of pressure ulcer was
nearly $22,000 in 1992.7 The same study found that
patients with a secondary diagnosis of pressure ulcer
incurred an average of $11,000 in additional hospital
charges.
Platelet-derived growth factor (PDGF) is a
dimeric protein of approximately 25 kDa, composed
of 2 disulfide-linked polypeptide chains.8 It exists in
3 different isoforms, the heterodimer PDGF-AB (con-
sisting of an A and B chain), and 2 homodimers, con-
sisting of 2 A or 2 B chains (PDGF-AA and PDGF-
BB, respectively). The homodimer PDGF-BB has been
shown in preclinical and clinical studies to promote
the formation of granulation tissue at the wound site
and to stimulate wound healing.9–12
Becaplermin (recombinant human PDGF-BB
[rhPDGF-BB]) is produced using recombinant DNA
technology by insertion of the gene for the B chain of
PDGF into the yeast Saccharomyces cerevisiae. The
biological activity of becaplermin has been shown to
be similar to that of naturally-occurring PDGF. 
Becaplermin is formulated in a preserved, sodium
carboxymethylcellulose-based gel for topical admin-
istration. This aqueous gel may provide the additional
benefit of a moist wound healing environment.12,13
Becaplermin gel has been approved in the United
States as an adjunct to good wound care for the treat-
ment of lower extremity diabetic neuropathic ulcers
that extend into the subcutaneous tissue or beyond
and have an adequate blood supply. Pressure ulcers
are another type of chronic full thickness wound, sim-
ilar to diabetic foot ulcers, and represent a potential
application for becaplermin gel treatment.
Results of previous studies of rhPDGF-BB treat-
ment of chronic stage III or IV pressure ulcers have
shown that doses of less than 100 µg/ml have little
effect on healing compared with placebo.14,15 However,
a phase II study involving 41 patients showed that,
when expressed as a percentage of initial ulcer vol-
ume, once-daily application of rhPDGF-BB 100 µg/ml
or 300 µg/ml resulted in a decrease in ulcer volume
at endpoint, a trend that approached significance
when compared with placebo (p = 0.056).16 The results
of these and other unpublished studies suggested a
need for further dose-ranging studies of rhPDGF-BB
for the treatment of pressure ulcers. Therefore, this
dose-ranging study evaluated the efficacy and safety
of becaplermin gel in the treatment of nonhealing full
thickness pressure ulcers compared with that of pla-
cebo gel in patients receiving a standardized regimen
of good wound care. 
MATERIALS AND METHODS
This study was a prospective, multicenter, double-
blind, parallel group, placebo-controlled trial involv-
ing a total of 124 patients (20 women and 104 men) ≥
18 years of age. Patients had at least 1 but no more
than 3 chronic full thickness (stage III or IV as defined
by the National Pressure Ulcer Advisory Panel)1 pres-
sure ulcers (primary or recurrent) without involve-
ment of bone tissue. To be eligible for the study, the
patient had to have a target ulcer with a volume be-
tween 10 ml and 150 ml, inclusive, following debride-
ment at the baseline visit. If more than 1 full thickness
ulcer was present, the investigator designated the ul-
cer that would presumably take the longest time to
heal as the target ulcer. Target ulcers had to be present
for at least 4 weeks despite previous treatment, and
had to be anatomically located where pressure could
be off-loaded for the duration of the study. Prior to
study entry, patients were required to have albumin
concentrations > 2.5 g/dl, total lymphocyte count >
1,000, and concentrations of vitamins A and C within
the normal range.
Before randomization, the target ulcer was de-
brided to remove all nonviable tissue. Quantitative
bacteriology was performed on tissue biopsy speci-
mens obtained from the center of the base of the ulcer.
Before debridement, any infection (defined from tis-
sue culture as the presence of >105 organisms per
gram of tissue) was treated followed by another tissue
culture until < 105 bacteria per gram of tissue were
present. Patients were excluded if: 1) osteomyelitis
affecting the area of the target ulcer was present; 2)
after debridement, the target ulcer volume (measured
by Jeltrate mold)17 was < 10 ml or > 150 ml; or 3)
topical antibiotics, antiseptics, enzymatic debriding
agents, or other agents that would interfere with
study evaluations had been used within the 7 days
preceding randomization. Patients with ulcers result-
ing from electrical, chemical, or radiation insult and
patients with cancer were excluded. Additional exclu-
sion criteria included concomitant diseases (e.g., con-
nective tissue disease), treatment (e.g., radiation
therapy), or medication (e.g., corticosteroids, chemo-
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therapy, or immunosuppressive agents) that would
deleteriously affect healing, or interfere with evalu-
ation of the study medication. Women who were preg-
nant, nursing, or of childbearing potential and not
using an acceptable method of birth control were ex-
cluded. The protocol was approved by the institutional
review boards and ethics committees at all sites, and
all patients gave written informed consent before en-
rolling in the study.
Study Design
Patients were randomly assigned to 1 of 4 parallel
treatment groups: 1) becaplermin gel 100 µg/g of
sodium carboxymethylcellulose vehicle gel (RE-
GRANEX® Gel 0.01%) (n = 31) once daily alternated
with placebo gel every 12 hours; 2) becaplermin gel
300 µg/g (n = 32) once daily alternated with placebo
gel every 12 hours; 3) becaplermin gel 100 µg/g twice
daily (n = 30); or 4) placebo gel (n = 31) twice daily.
A thin layer of study drug (becaplermin gel or placebo
gel) was placed on the entire exposed wound surface,
and the wound was then packed with saline-moist-
ened gauze. All study sites received dressing supplies
to ensure a uniform regimen. The second daily dress-
ing was applied in a similar fashion after gently
rinsing the wound surface with saline or water. Study
medication was administered in conjunction with a
standardized regimen of good wound care for
16 weeks or until the target ulcer was completely
healed, whichever came first.
Debridement of ulcers to remove fibrin and ne-
crotic tissue was an important component of good
wound care and was performed by investigators dur-
ing clinic visits if necessary. Good wound care also
included culture of tissue biopsy specimens to rule
out infection, systemic treatment of wound infections,
off-loading of pressure from the affected area, main-
tenance of a moist wound environment, and nutri-
tional support as needed. Efficacy and safety
evaluations were performed at each visit.
Efficacy Evaluations
Efficacy evaluations were based on functional assess-
ment of the ulcer (completely healed or < completely
healed, scored as 1 or 2, respectively), ulcer volume
measurements (determined by Jeltrate mold) and ul-
cer area measurements (determined by planimetric
analyses of acetate tracings). The primary efficacy
endpoint was the incidence of complete healing. Ad-
ditional efficacy endpoints included incidence of ≥ 90%
healing and relative ulcer volume at endpoint (end-
point volume/baseline volume).
Safety Evaluations
Safety was evaluated by monitoring adverse events
(AEs), serious adverse events (SAEs), deaths, discon-
tinuations, clinical laboratory measurements, and vi-
tal signs. Serum samples were collected at baseline
and upon completion of the study for the evaluation of
antibecaplermin antibody formation. Adverse events
were monitored by open-ended questioning of patients
by investigators. A treatment-emergent AE was de-
fined as an AE that was either not present at baseline
or, if present at baseline, increased in severity as the
study progressed. Serious adverse events were AEs
that were either immediately life threatening, perma-
nently or significantly disabling, required a prolonged
hospitalization, resulted in long-term outpatient
treatment, or resulted in a congenital anomaly, cancer,
or death.
Statistical Methods
All statistical analyses were based on the intent-to-
treat population. The primary endpoint, incidence of
complete healing, was analyzed using the Cochran-
Mantel Haenszel test, which evaluated the associa-
tion between the response variable and treatments,
while adjusting for the effects of study center. Because
the incidence of complete healing in the control group
was 0, the incidence of and time to 90% ulcer closure
were also analyzed. The incidence of 90% closure was
analyzed using the Cochran-Mantel Haenszel test,
and the significance of differences in time to 90%
closure was assessed using the Cox proportional haz-
ards model with baseline ulcer volume as a covariate.
The relative ulcer volume, defined as the ulcer vol-
ume at the end of the study divided by the ulcer volume
at baseline, was analyzed using an analysis of covari-
ance model with terms for treatment effect, center ef-
fect, and baseline ulcer volume effect, with tests for
the relevant interactions. All hypotheses regarding in-
teractions were tested at a significance level of 0.10.
All hypotheses regarding comparisons of the ac-
tive treatment to the vehicle control were 2-sided,
performed at the 0.05 level of significance. To ascer-
tain the dose–response relationship, the Cochran-
Armitage trend test was used for complete and 90%
wound closure parameters. The trend test was one-
sided at the 0.025 level against the alternative of a
linearly increasing dose–response.
RESULTS
A total of 124 patients from 14 study sites were as-
signed randomly to the various treatment groups. No
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clinically important differences between treatment
groups were observed for any of the demographic or
baseline efficacy variables (Table 1).
Efficacy Results
In the groups treated with either dose of becaplermin
gel once daily (100 µg/g or 300 µg/g), the incidence of
complete healing was significantly greater compared
with that of placebo gel (23% and 19% for the 100 µg/
g and 300 µg/g becaplermin gel treatment groups,
respectively, vs. 0% for the placebo gel treatment
group, p = 0.005 and p = 0.008, respectively; Figure
1). A similar difference was observed in the incidence
of ≥ 90% healing: 58% and 59% for the 100 µg/g and
300 µg/g becaplermin gel treatment groups, respec-
tively, vs. 29% for the placebo gel treatment group,
p = 0.021 and p = 0.014, respectively, (Figure 2). The
incidences of complete and ≥ 90% healing were 3%
and 40%, respectively, in patients receiving becapler-
min gel 100 µg/g twice daily.
The median relative ulcer volume at endpoint was
0.07 and 0.05 in the becaplermin gel 100 µg/g and
300 µg/g treatment groups, respectively, compared
with 0.27 in the placebo gel group (p = 0.013 and p =
0.011, respectively, Figure 3). Median relative ulcer
volume at endpoint was 0.15 in the group receiving
becaplermin gel 100 µg/g twice daily.
Safety Results
Safety evaluations were based on the intent-to-treat
population of 124 patients. The overall incidence of
treatment-emergent AEs was similar for all 4 treat-
ment groups. The majority of these events were mild
to moderate in severity and were generally consistent
with the underlying disease state and age of the pa-
tient population. These included, but were not limited
to, skin ulceration, urinary tract infection, skin dis-
order (e.g., rash, erythema), and fever. No deaths oc-
curred during the treatment phase of the study.
A total of 21 patients (4 patients receiving pla-
cebo gel, 2 patients receiving becaplermin gel 100
µg/g once daily, 6 patients receiving becaplermin gel
Table 1. Patient demographic and clinical characteristics at study inclusion
Becaplermin gel
Characteristic Placebo gel 100 µg/g 300 µg/g 100 µg/g BID
Gender
Male 25 (81)a 26 (84) 27 (84) 26 (87)
Female 6 (19) 5 (16) 5 (16) 4 (13)
Age (years)* 50 ± 13.6 48 ± 13.1 49 ± 12.5 51 ± 18.3
Target ulcer volume (ml)† 19.6 ± 21.9 16.6 ± 15.1 17.2 ± 19.7 17.6 ± 33.8
Duration of ulcer (weeks)† 30 ± 43 22 ± 32 33 ± 40 22 ± 52
aValues indicate number and percent of total in parentheses
*Mean ± standard deviation
†Median ± interquartile range.
Figure 1. Incidence of complete healing in all treatment groups.
Individuals in the 100 and 300 µg/g groups received active gel
once a day. Figure 2. Incidence of ≥90% healing in the four treatment groups.
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300 µg/g once daily, and 9 patients receiving beca-
plermin gel 100 µg/g twice daily) experienced SAEs.
All of these events were considered unrelated to
study medication.
The incidence of wound-related, treatment-emer-
gent AEs was similar among the 4 treatment groups:
2 patients in each of the placebo gel, becaplermin gel
100 µg/g once-daily and twice-daily treatment groups,
and 3 patients in the becaplermin gel 300 µg/g group
(Table 2). One patient treated with becaplermin gel
100 µg/g twice daily discontinued the study prema-
turely because of worsening condition of the ulcer;
however, the patient reported placing pressure on the
ulcer on multiple occasions between study visits, and
the event was considered unlikely to be related to
study medication.
Of the 103 patients who had pre- and post-study
serum samples available for evaluation of anti-beca-
plermin serum antibodies, 6 tested positive. These
included 2 patients from each of the 3 becaplermin
gel treatment groups; none of the patients treated
with placebo gel developed antibodies to becaplermin.
Post-study sera from these patients inhibited the
binding of excess free becaplermin in a competitive
ELISA format by 18% to 78%. None of these sera,
however, were able to inhibit becaplermin-induced
proliferation in a fibroblast mitogenesis assay, indi-
cating that the antibodies did not neutralize the bi-
ological activity of becaplermin 
Changes in clinical laboratory values (levels of
glucose, blood urea nitrogen, creatinine, aspartate
transaminase, alanine transaminase, serum albumin,
hemoglobin, and urine albumin) were comparable for
the 4 treatment groups and were not related to study
treatment. There were no clinically significant
changes from baseline in vital signs in any patients
in the 4 treatment groups.
DISCUSSION
Once-daily treatment of chronic pressure ulcers with
becaplermin gel significantly increased the incidences
of complete and ≥90% healing; in contrast, none of
the patients treated with placebo gel achieved com-
plete healing by the end of the study. Of note, patients
treated with becaplermin gel 300 µg/g showed no ad-
ditional clinical benefit beyond that observed in pa-
tients treated with becaplermin gel 100 µg/g once
daily. It is unclear why the group receiving becapler-
min gel 100 µg/g twice daily did not show a significant
benefit compared with placebo gel. Analysis of base-
line ulcer volume and ulcer duration did not show a
pattern that would explain the reduced incidence of
complete and ≥ 90% healing that was observed in the
twice-daily treatment group.
The secondary endpoint, ≥ 90% healing, was cho-
sen based on reports in the literature indicating that
patients benefit substantially from achieving consid-
erable but incomplete healing (i.e., 90% healing).18–
20 Healing to 90%, which largely reflects granulation
tissue formation and contraction of the ulcer, is a
relatively rapid process and is followed by a slower
Figure 3. Median relative ulcer volume at each visit. Relative
ulcer volume is the volume at an indicated week divided by
the baseline volume.
Table 2. Wound infection-related adverse events associated with the target ulcer
Becaplermin gel
Adverse event Placebo gel 100 µg/g 300 µg/g 100 µg/g BID
n 31 31 32 30
Condition aggravated 0 (0)a 0 (0) 1 (3) 1(3)
Osteomyelitis 1 (3) 2 (6) 1 (3) 0 (0)
Infection 1 (3) 0 (0) 0 (0) 1 (3)
Sepsis 0 (0) 0 (0) 1 (3) 0 (0)
Any adverse event 2 (6) 2 (6) 3 (9) 2 (7)
aValues indicate number of AEs with percent of total in parentheses
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progression to epithelialization and complete resur-
facing.20 Further validation of 90% healing as a clin-
ically relevant endpoint was provided by a study that
investigated patterns of wound healing in people with
diabetes. Results of this study showed that the rate
of change in area was approximately linear during
the first month of observation. The pattern of change
in area, however, progressively decreased as the
wound approached total closure.18
To investigate the effect of becaplermin gel treat-
ment on the ease of surgical wound closure, a blinded
retrospective evaluation based on photographs was
also conducted in this study and reported by Robson
and colleagues.21 Although all 4 treatment groups
showed a significant improvement compared with
baseline evaluations, the results suggest that beca-
plermin gel treatment results in greater ease of wound
closure, and may subsequently reduce the need for
myocutaneous flap surgery, an expensive procedure
associated with high morbidity, to a more simple pro-
cedure requiring a few sutures placed for approxima-
tion, a procedure that can be performed at bedside.
Consistent with results of clinical studies of be-
caplermin gel for treatment of lower extremity dia-
betic ulcers, treatment of patients with chronic
pressure ulcers was well tolerated and there were no
safety concerns associated with the use of becaplermin
gel.10–12 The majority of AEs were similar in incidence
across treatment groups, were considered unlikely to
be related to study medication, and were generally
consistent with the underlying disease state and age
of the patient population.
In conclusion, the results of this study suggest
that within the setting of a comprehensive wound
management program, becaplermin gel 100 µg/g once
daily increases the incidence of complete healing and
≥90% healing in patients with full thickness pressure
ulcers. Becaplermin gel also has an excellent safety
profile. Moreover, the economic implications of the
results of this and other studies using becaplermin
gel may be significant. By increasing the incidence of
healing, becaplermin gel may potentially reduce the
costs associated with pressure ulcer treatment, which
are estimated at 1.5 billion dollars annually across
all treatment settings. Future studies are warranted
to address issues such as the effect of becaplermin
gel on healthcare resource utilization and patient
quality of life.
APPENDIX
The members of the Pressure Ulcer Study Group are:
J. J. Biundo, MD, Louisiana State University Medical
Center, New Orleans, LA; A. E. Cram, MD, University
of Iowa Hospitals and Clinics, Iowa City, IA; I. Eltorai,
MD, Long Beach VA Medical Center, Long Beach, CA;
R. H. K. Eng, MD, East Orange VA Medical Center,
East Orange, NJ; S. Gupta, MD, MetroWest Medical
Center, Framingham, MA; J. W. Harmon, MD, VA
Medical Center, Washington, DC; A. Luterman, MD,
University of South Alabama, Mobile, AL; B. A. Nem-
chausky, MD, The Edward J. Hines, Jr VA Hospital,
Hines, IL; L. Phillips, MD, University of Texas Med-
ical Branch, Galveston, TX; A. Pozez, MD, Medical
College of Virginia, Richmond, VA; R. Read, MD, John
L. McClellan Memorial Veterans Hospital, Little
Rock, AR; E. E. Tredget, MD, MacKenzie Health Sci-
ences Center, Edmonton, Alberta, Canada.
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